Proteon Therapeutics, Inc. Announces Positive Phase 2 Trial Results of PRT-201 in Chronic Kidney Disease Patients Undergoing Surgical Placement of an Arteriovenous Fistula for Hemodialysis
1/4/2013 9:52:43 AM
More...
|
Awaiting Novartis AG Acquisition, Biotech Firm Proteon Therapeutics, Inc. Raises $15.2 Million
8/12/2011 8:04:43 AM
More...
|
Proteon Therapeutics, Inc. Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
4/14/2011 12:38:48 PM
More...
|
Proteon Therapeutics, Inc. Named 2010 Technology Pioneer by the World Economic Forum
12/3/2009 9:08:16 AM
More...
|
Proteon Therapeutics, Inc. Completes Second Closing of Equity Financing; Raises Total Series B to $50 Million
5/28/2009 7:27:50 AM
More...
|
Proteon Therapeutics, Inc. Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement to Sell for $550 Million
3/5/2009 7:21:58 AM
More...
|
Proteon Therapeutics, Inc. Presents New Data on PRT-201 at the Annual Meeting of the American Society of Nephrology in Philadelphia
11/6/2008 9:38:10 AM
More...
|
Proteon Therapeutics, Inc. to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
10/13/2008 11:30:52 AM
More...
|
Proteon Therapeutics, Inc. Receives FDA Fast Track Designation for First Drug Candidate PRT–201
9/10/2008 9:17:35 AM
More...
|
Proteon Therapeutics, Inc. Receives European Patent Covering New Method of Dilating Arteries and Veins
3/14/2008 6:31:48 AM
More...
|
|